REC 3565
Alternative Names: EXS-73565; REC-3565; ‘565Latest Information Update: 13 May 2025
At a glance
- Originator Exscientia
- Developer Bristol-Myers Squibb; Exscientia; Recursion Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Haematological malignancies
- Phase I B-cell lymphoma
Most Recent Events
- 05 May 2025 Phase-I/II clinical trials in Haematological malignancies (unspecified route), Prior to May 2025
- 31 Mar 2025 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in Spain, United Kingdom (PO) (NCT06980116)
- 07 Jan 2025 UK Medicines and Healthcare Products Regulatory Agency (MHRA) approves clinical trial application for REC-3565 in B cell malignancies